CN1875936A - 含克罗拉滨和细胞毒药物的抗癌缓释剂 - Google Patents
含克罗拉滨和细胞毒药物的抗癌缓释剂 Download PDFInfo
- Publication number
- CN1875936A CN1875936A CNA2006102007015A CN200610200701A CN1875936A CN 1875936 A CN1875936 A CN 1875936A CN A2006102007015 A CNA2006102007015 A CN A2006102007015A CN 200610200701 A CN200610200701 A CN 200610200701A CN 1875936 A CN1875936 A CN 1875936A
- Authority
- CN
- China
- Prior art keywords
- copolymer
- acid
- clofarabine
- slow
- release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000001093 anti-cancer Effects 0.000 title claims abstract description 39
- 238000013268 sustained release Methods 0.000 title claims description 56
- 239000012730 sustained-release form Substances 0.000 title claims description 56
- 239000003795 chemical substances by application Substances 0.000 title claims description 15
- 229940127089 cytotoxic agent Drugs 0.000 title 1
- 239000002254 cytotoxic agent Substances 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract description 119
- 239000007924 injection Substances 0.000 claims abstract description 111
- 238000002347 injection Methods 0.000 claims abstract description 111
- WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 claims abstract description 107
- 229960000928 clofarabine Drugs 0.000 claims abstract description 107
- 239000004626 polylactic acid Substances 0.000 claims abstract description 58
- 229920000747 poly(lactic acid) Polymers 0.000 claims abstract description 53
- 229920001577 copolymer Polymers 0.000 claims abstract description 51
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 39
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 39
- 239000000463 material Substances 0.000 claims abstract description 26
- 229960004783 fotemustine Drugs 0.000 claims abstract description 25
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 claims abstract description 25
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims abstract description 24
- 229960003668 docetaxel Drugs 0.000 claims abstract description 24
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000001768 carboxy methyl cellulose Substances 0.000 claims abstract description 15
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims abstract description 15
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims abstract description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 56
- HYHJFNXFVPGMBI-UHFFFAOYSA-N 2-[[2-chloroethyl(nitroso)carbamoyl]-methylamino]acetamide Chemical compound NC(=O)CN(C)C(=O)N(CCCl)N=O HYHJFNXFVPGMBI-UHFFFAOYSA-N 0.000 claims description 48
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 44
- 230000007541 cellular toxicity Effects 0.000 claims description 42
- 239000002904 solvent Substances 0.000 claims description 38
- 239000007943 implant Substances 0.000 claims description 36
- 239000004005 microsphere Substances 0.000 claims description 36
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 28
- 229960002949 fluorouracil Drugs 0.000 claims description 28
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 claims description 28
- LPGWZGMPDKDHEP-HLTPFJCJSA-N Leurosine Chemical compound C([C@]1([C@@H]2O1)CC)N(CCC=1C3=CC=CC=C3NC=11)C[C@H]2C[C@]1(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC LPGWZGMPDKDHEP-HLTPFJCJSA-N 0.000 claims description 24
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 claims description 24
- 229960001842 estramustine Drugs 0.000 claims description 24
- 239000000375 suspending agent Substances 0.000 claims description 24
- 229960003048 vinblastine Drugs 0.000 claims description 24
- HAWSQZCWOQZXHI-FQEVSTJZSA-N 10-Hydroxycamptothecin Chemical compound C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-FQEVSTJZSA-N 0.000 claims description 23
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 23
- 229920000305 Nylon 6,10 Polymers 0.000 claims description 23
- 239000003513 alkali Substances 0.000 claims description 23
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 23
- 229960001101 ifosfamide Drugs 0.000 claims description 23
- QXYYYPFGTSJXNS-UHFFFAOYSA-N mitozolomide Chemical compound N1=NN(CCCl)C(=O)N2C1=C(C(=O)N)N=C2 QXYYYPFGTSJXNS-UHFFFAOYSA-N 0.000 claims description 23
- 229950005967 mitozolomide Drugs 0.000 claims description 23
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 claims description 22
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 22
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims description 22
- 229960002932 anastrozole Drugs 0.000 claims description 22
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 22
- 229960005420 etoposide Drugs 0.000 claims description 22
- 229960002247 lomustine Drugs 0.000 claims description 22
- 238000002360 preparation method Methods 0.000 claims description 22
- 229960001603 tamoxifen Drugs 0.000 claims description 22
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims description 22
- 229960001278 teniposide Drugs 0.000 claims description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 20
- 238000011282 treatment Methods 0.000 claims description 19
- 229920001244 Poly(D,L-lactide) Polymers 0.000 claims description 18
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 18
- 239000002689 soil Substances 0.000 claims description 18
- 229960004964 temozolomide Drugs 0.000 claims description 18
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 15
- 239000003005 anticarcinogenic agent Substances 0.000 claims description 15
- JVYNJRBSXBYXQB-UHFFFAOYSA-N 4-[3-(4-carboxyphenoxy)propoxy]benzoic acid;decanedioic acid Chemical compound OC(=O)CCCCCCCCC(O)=O.C1=CC(C(=O)O)=CC=C1OCCCOC1=CC=C(C(O)=O)C=C1 JVYNJRBSXBYXQB-UHFFFAOYSA-N 0.000 claims description 14
- 229950004403 polifeprosan Drugs 0.000 claims description 14
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 12
- 239000005038 ethylene vinyl acetate Substances 0.000 claims description 12
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims description 12
- 239000000600 sorbitol Substances 0.000 claims description 12
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 11
- 229930195725 Mannitol Natural products 0.000 claims description 11
- 229920000954 Polyglycolide Polymers 0.000 claims description 11
- 239000000194 fatty acid Substances 0.000 claims description 11
- 239000000594 mannitol Substances 0.000 claims description 11
- 235000010355 mannitol Nutrition 0.000 claims description 11
- 239000004633 polyglycolic acid Substances 0.000 claims description 11
- 229960004275 glycolic acid Drugs 0.000 claims description 9
- OFJWFSNDPCAWDK-UHFFFAOYSA-N 2-phenylbutyric acid Chemical compound CCC(C(O)=O)C1=CC=CC=C1 OFJWFSNDPCAWDK-UHFFFAOYSA-N 0.000 claims description 8
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 claims description 8
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 7
- 239000004094 surface-active agent Substances 0.000 claims description 7
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 5
- 229920002125 Sokalan® Polymers 0.000 claims description 5
- YADZBEISHVCBSJ-UHFFFAOYSA-N [I].OCC(O)CO Chemical compound [I].OCC(O)CO YADZBEISHVCBSJ-UHFFFAOYSA-N 0.000 claims description 5
- 229960001631 carbomer Drugs 0.000 claims description 5
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 claims description 5
- 238000002513 implantation Methods 0.000 claims description 5
- 229940083037 simethicone Drugs 0.000 claims description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 4
- 210000004204 blood vessel Anatomy 0.000 claims description 3
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 claims description 3
- 210000003169 central nervous system Anatomy 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 210000001165 lymph node Anatomy 0.000 claims description 3
- 210000001685 thyroid gland Anatomy 0.000 claims description 3
- 201000000274 Carcinosarcoma Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 210000003679 cervix uteri Anatomy 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 210000004696 endometrium Anatomy 0.000 claims description 2
- 210000003238 esophagus Anatomy 0.000 claims description 2
- 210000001508 eye Anatomy 0.000 claims description 2
- 210000000232 gallbladder Anatomy 0.000 claims description 2
- 210000004907 gland Anatomy 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 210000005075 mammary gland Anatomy 0.000 claims description 2
- 210000000214 mouth Anatomy 0.000 claims description 2
- 210000004877 mucosa Anatomy 0.000 claims description 2
- 210000001989 nasopharynx Anatomy 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 210000000664 rectum Anatomy 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 210000003932 urinary bladder Anatomy 0.000 claims description 2
- 210000004291 uterus Anatomy 0.000 claims description 2
- 229960004063 propylene glycol Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 44
- 239000000725 suspension Substances 0.000 abstract description 14
- 239000002671 adjuvant Substances 0.000 abstract description 4
- 239000000470 constituent Substances 0.000 abstract description 3
- 239000002253 acid Substances 0.000 abstract 2
- 231100000433 cytotoxic Toxicity 0.000 abstract 2
- 230000001472 cytotoxic effect Effects 0.000 abstract 2
- 125000001931 aliphatic group Chemical group 0.000 abstract 1
- 229930013930 alkaloid Natural products 0.000 abstract 1
- 150000003797 alkaloid derivatives Chemical class 0.000 abstract 1
- 229940100198 alkylating agent Drugs 0.000 abstract 1
- 239000002168 alkylating agent Substances 0.000 abstract 1
- 229940125532 enzyme inhibitor Drugs 0.000 abstract 1
- 239000002532 enzyme inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 description 41
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- 239000000203 mixture Substances 0.000 description 19
- 210000004881 tumor cell Anatomy 0.000 description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 229920000642 polymer Polymers 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 229960004756 ethanol Drugs 0.000 description 14
- 239000000546 pharmaceutical excipient Substances 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 238000002156 mixing Methods 0.000 description 12
- 238000007920 subcutaneous administration Methods 0.000 description 12
- 230000004614 tumor growth Effects 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 230000012010 growth Effects 0.000 description 9
- 238000001694 spray drying Methods 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 8
- 239000011859 microparticle Substances 0.000 description 8
- 229920002101 Chitin Polymers 0.000 description 7
- 102000008186 Collagen Human genes 0.000 description 7
- 108010035532 Collagen Proteins 0.000 description 7
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 7
- -1 chrondroitin Polymers 0.000 description 7
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 7
- 229920001542 oligosaccharide Polymers 0.000 description 7
- 150000002482 oligosaccharides Chemical class 0.000 description 7
- 238000010254 subcutaneous injection Methods 0.000 description 7
- 239000007929 subcutaneous injection Substances 0.000 description 7
- 230000001629 suppression Effects 0.000 description 7
- 239000000811 xylitol Substances 0.000 description 7
- 235000010447 xylitol Nutrition 0.000 description 7
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 7
- 229960002675 xylitol Drugs 0.000 description 7
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 6
- 239000008273 gelatin Substances 0.000 description 6
- 229920000159 gelatin Polymers 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 235000011852 gelatine desserts Nutrition 0.000 description 6
- 229920002674 hyaluronan Polymers 0.000 description 6
- 229960003160 hyaluronic acid Drugs 0.000 description 6
- 229920002521 macromolecule Polymers 0.000 description 6
- 239000000693 micelle Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 108010088751 Albumins Proteins 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 4
- 229920002732 Polyanhydride Polymers 0.000 description 4
- 229920001400 block copolymer Polymers 0.000 description 4
- 201000008275 breast carcinoma Diseases 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000007334 copolymerization reaction Methods 0.000 description 4
- 238000011978 dissolution method Methods 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000007710 freezing Methods 0.000 description 4
- 230000008014 freezing Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000003292 glue Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000011275 oncology therapy Methods 0.000 description 4
- 235000010603 pastilles Nutrition 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000003349 gelling agent Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000011125 single therapy Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 2
- 206010052804 Drug tolerance Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 229920005576 aliphatic polyanhydride Polymers 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 229960000935 dehydrated alcohol Drugs 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 208000018389 neoplasm of cerebral hemisphere Diseases 0.000 description 2
- 238000007500 overflow downdraw method Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 229920001432 poly(L-lactide) Polymers 0.000 description 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 2
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 description 2
- 229950008885 polyglycolic acid Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 208000023958 prostate neoplasm Diseases 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 208000034530 PLAA-associated neurodevelopmental disease Diseases 0.000 description 1
- 229920000436 Poly(lactide-co-glycolide)-block-poly(ethylene glycol)-block-poly(lactide-co-glycolide) Polymers 0.000 description 1
- 229920001273 Polyhydroxy acid Polymers 0.000 description 1
- 229920000432 Polylactide-block-poly(ethylene glycol)-block-polylactide Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 239000011258 core-shell material Substances 0.000 description 1
- LPRCVLBATUMNBP-UHFFFAOYSA-N decanedioic acid;propane Chemical compound CCC.OC(=O)CCCCCCCCC(O)=O LPRCVLBATUMNBP-UHFFFAOYSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000012155 injection solvent Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000011806 microball Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000003361 porogen Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- DSNYFFJTZPIKFZ-UHFFFAOYSA-N propoxybenzene Chemical compound CCCOC1=CC=CC=C1 DSNYFFJTZPIKFZ-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
试验组(n) | 所受治疗 | 肿瘤体积(cm3) | P值 |
1(6) | 对照 | 64±10 | |
2(6) | 克罗拉滨 | 42±5.2 | <0.05 |
3(6) | 羟基喜树硷 | 40±2.2 | <0.01 |
4(6) | 米托唑胺 | 44±2.6 | <0.01 |
5(6) | 多西他赛 | 42±3.4 | <0.01 |
6(6) | 异环磷酰胺 | 42±3.6 | <0.01 |
7(6) | 羟基喜树硷+克罗拉滨 | 18±2.0 | <0.001 |
8(6) | 米托唑胺+克罗拉滨 | 16±2.2 | <0.001 |
9(6) | 多西他赛+克罗拉滨 | 20±2.0 | <0.001 |
10(6) | 异环磷酰胺+克罗拉滨 | 28±2.0 | <0.001 |
瘤细胞 | 克罗拉滨 | 洛莫司汀 | 雌莫司汀 | 福莫司汀 | 洛莫司汀+克罗拉滨 | 雌莫司汀+克罗拉滨 | 福莫司汀+克罗拉滨 |
CNS | 52% | 42% | 36% | 26% | 82% | 76% | 84% |
C6 | 62% | 50% | 38% | 24% | 84% | 86% | 92% |
SA | 62% | 40% | 22% | 26% | 88% | 88% | 90% |
BC | 56% | 44% | 24% | 24% | 84% | 86% | 82% |
BA | 54% | 40% | 22% | 28% | 88% | 78% | 78% |
LH | 68% | 50% | 22% | 28% | 80% | 86% | 82% |
PAT | 62% | 46% | 28% | 26% | 90% | 86% | 84% |
试验组(n) | 所受治疗 | 肿瘤体积(cm3) | P值 |
1(6) | 对照 | 66±12 | |
2(6) | 克罗拉滨 | 44±4.2 | <0.05 |
3(6) | 萨莫司汀 | 42±2.0 | <0.01 |
4(6) | 克罗拉滨+萨莫司汀 | 22±2.2 | <0.001 |
5(6) | 依托泊甙 | 38±3.2 | <0.01 |
6(6) | 克罗拉滨+依托泊甙 | 22±1.6 | <0.001 |
7(6) | 替尼泊甙 | 32±2.6 | <0.01 |
8(6) | 克罗拉滨+替尼泊甙 | 18±2.4 | <0.001 |
9(6) | 长春花碱 | 38±4.0 | <0.01 |
10(6) | 克罗拉滨+长春花碱 | 22±2.0 | <0.001 |
试验组(n) | 所受治疗 | 肿瘤抑制率(%) | P值 |
1(6) | 对照 | - | |
2(6) | 克罗拉滨 | 46 | <0.05 |
3(6) | 阿那曲唑 | 36 | <0.01 |
4(6) | 他莫昔芬 | 44 | <0.01 |
5(6) | 氟尿嘧啶 | 52 | <0.01 |
6(6) | 丝裂霉素C | 42 | <0.01 |
7(6) | 克罗拉滨+阿那曲唑 | 72 | <0.001 |
8(6) | 克罗拉滨+他莫昔芬 | 80 | <0.001 |
9(6) | 克罗拉滨+氟尿嘧啶 | 82 | <0.001 |
10(6) | 克罗拉滨+丝裂霉素C | 82 | <0.001 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200610200701A CN1875936B (zh) | 2006-07-18 | 2006-07-18 | 含克罗拉滨和细胞毒药物的抗癌缓释剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200610200701A CN1875936B (zh) | 2006-07-18 | 2006-07-18 | 含克罗拉滨和细胞毒药物的抗癌缓释剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1875936A true CN1875936A (zh) | 2006-12-13 |
CN1875936B CN1875936B (zh) | 2010-05-19 |
Family
ID=37508611
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200610200701A Expired - Fee Related CN1875936B (zh) | 2006-07-18 | 2006-07-18 | 含克罗拉滨和细胞毒药物的抗癌缓释剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1875936B (zh) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003287081A1 (en) * | 2002-10-16 | 2004-05-04 | Ilex Products, Inc. | Clofarabine and taxane chemotherapy combination |
WO2004035043A1 (en) * | 2002-10-16 | 2004-04-29 | Ilex Products, Inc. | Clofarabine and platinum chemotherapy combination |
CN1875935A (zh) * | 2006-07-18 | 2006-12-13 | 济南康泉医药科技有限公司 | 一种含克罗拉滨和细胞毒药物的抗癌缓释剂 |
-
2006
- 2006-07-18 CN CN200610200701A patent/CN1875936B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1875936B (zh) | 2010-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1857221A (zh) | 一种同载铂类化合物及其增效剂的抗癌缓释剂 | |
CN1868453A (zh) | 一种同载铂类化合物和细胞毒药物的缓释注射剂 | |
CN1861053A (zh) | 含铂类化合物和细胞毒药物的抗癌缓释注射剂 | |
CN1857217A (zh) | 一种含雌激素受体拮抗剂的抗癌缓释注射剂 | |
CN1861052A (zh) | 一种含铂类化合物和细胞毒药物的抗癌缓释注射剂 | |
CN1861051A (zh) | 一种含铂类化合物及其增效剂的抗癌缓释注射剂 | |
CN1861054A (zh) | 一种含舒铂等铂类化合物的复方抗癌缓释剂 | |
CN1957913A (zh) | 同载铂类化合物和间质水解剂的抗癌药物组合物 | |
CN1875935A (zh) | 一种含克罗拉滨和细胞毒药物的抗癌缓释剂 | |
CN1887265A (zh) | 一种抗癌缓释剂 | |
CN1957923A (zh) | 一种同载氟尿嘧啶及其增效剂的缓释注射剂 | |
CN1839843A (zh) | 氟尿嘧啶缓释注射剂 | |
CN1887268A (zh) | 一种新的抗癌缓释注射剂 | |
CN1887269A (zh) | 一种含苯达莫司汀及其增效剂的抗癌缓释注射剂 | |
CN1957919A (zh) | 一种含氟尿嘧啶及其增效剂的缓释剂 | |
CN1875936A (zh) | 含克罗拉滨和细胞毒药物的抗癌缓释剂 | |
CN1927171A (zh) | 含四唑紫罗兰和细胞毒药物的抗癌缓释剂 | |
CN1887264A (zh) | 一种含苯达莫司汀的复方抗癌缓释剂 | |
CN1850051A (zh) | 一种同载血管抑制剂和细胞毒药物的抗癌缓释注射剂 | |
CN1887257A (zh) | 同载铂类化合物和克罗拉滨的抗癌药物组合物 | |
CN1927176A (zh) | 一种含四唑紫罗兰和细胞毒药物的抗癌缓释剂 | |
CN1875937A (zh) | 一种同载克罗拉滨和细胞毒药物的缓释注射剂 | |
CN1927178A (zh) | 一种同载四唑紫罗兰和细胞毒药物的缓释注射剂 | |
CN1957921A (zh) | 同载氟尿嘧啶及其增效剂的缓释注射剂 | |
CN1973824A (zh) | 同载铂类化合物和雷帕霉素的抗癌组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP02 | Change in the address of a patent holder |
Address after: High tech Zone Tianchen road Ji'nan City, Shandong province 250101 No. 1750 Patentee after: Jinan Kangquan Medicine Sci. & Tech. Co., Ltd. Address before: 206, room 2, building 19, Pioneer Park, No. 250100 Huaneng Road, Shandong, Ji'nan Patentee before: Jinan Kangquan Medicine Sci. & Tech. Co., Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: SHANDONG LANJIN BIOENGINEERING CO., LTD. Free format text: FORMER OWNER: JINAN KANGQUAN MEDICINE SCI. + TECH. CO., LTD. Effective date: 20120807 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20120807 Address after: High tech Zone Tianchen road Ji'nan City, Shandong province 250101 No. 1750 Patentee after: Shandong Lanjin Pharmaceuticals Co., Ltd. Address before: High tech Zone Tianchen road Ji'nan City, Shandong province 250101 No. 1750 Patentee before: Jinan Kangquan Medicine Sci. & Tech. Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100519 Termination date: 20160718 |
|
CF01 | Termination of patent right due to non-payment of annual fee |